178 related articles for article (PubMed ID: 38391833)
1. Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape.
Kostadinov K; Marinova Y; Dimitrov K; Hristova-Atanasova E; Iskrov G; Stefanov R
Healthcare (Basel); 2024 Feb; 12(4):. PubMed ID: 38391833
[TBL] [Abstract][Full Text] [Related]
2. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries.
Kamusheva M; Vassileva M; Savova A; Manova M; Petrova G
Front Public Health; 2018; 6():61. PubMed ID: 29556491
[TBL] [Abstract][Full Text] [Related]
3. Analysis of patients' access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece.
Seitaridou Y; Tsekov I; Kamusheva M; Dimitrova M; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):241-246. PubMed ID: 34525887
[TBL] [Abstract][Full Text] [Related]
4. Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.
Kostadinov K; Popova-Sotirova I; Marinova Y; Musurlieva N; Iskrov G; Stefanov R
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672571
[TBL] [Abstract][Full Text] [Related]
5. Affordability of medicines in the European Union.
Zaprutko T; Kopciuch D; Kus K; Merks P; Nowicka M; Augustyniak I; Nowakowska E
PLoS One; 2017; 12(2):e0172753. PubMed ID: 28241019
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria.
Karanyotova S; Topova B; Petrova E; Doychev P; Kapitanska E; Petrova G; Mitkova Z; Dimitrova M
Front Public Health; 2023; 11():1073733. PubMed ID: 36935674
[TBL] [Abstract][Full Text] [Related]
7. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
8. PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.
Benisheva-Dimitrova T; Sidjimova D; Cherneva D; Kralimarkov N
Int J Technol Assess Health Care; 2017 Jan; 33(3):365-370. PubMed ID: 28831942
[TBL] [Abstract][Full Text] [Related]
9. Drug Policy in Bulgaria.
Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
[TBL] [Abstract][Full Text] [Related]
10. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
Vončina L; Strbad T; Fürst J; Dimitrova M; Kamusheva M; Vila M; Mardare I; Hristova K; Harsanyi A; Atanasijević D; Banović I; Bobinac A
Appl Health Econ Health Policy; 2021 Nov; 19(6):915-927. PubMed ID: 34553334
[TBL] [Abstract][Full Text] [Related]
11. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
[TBL] [Abstract][Full Text] [Related]
12. Access to medicines for rare diseases: A European regulatory roadmap for academia.
Rosenberg N; van den Berg S; Stolwijk NN; Jacobs BAW; Post HC; Pasmooij AMG; de Visser SJ; Hollak CEM
Front Pharmacol; 2023; 14():1142351. PubMed ID: 36925633
[No Abstract] [Full Text] [Related]
13. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States.
Vogler S; Habl C; Bogut M; Voncina L
Croat Med J; 2011 Apr; 52(2):183-97. PubMed ID: 21495202
[TBL] [Abstract][Full Text] [Related]
14. Access to orphan drugs - comparison across Balkan countries.
Pejcic AV; Iskrov G; Jakovljevic MM; Stefanov R
Health Policy; 2018 Jun; 122(6):583-589. PubMed ID: 29729905
[TBL] [Abstract][Full Text] [Related]
15. Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective.
Tafuri G; Bracco A; Grueger J
Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):381-389. PubMed ID: 34930086
[TBL] [Abstract][Full Text] [Related]
16. Market access pathways for cell therapies in France.
Rémuzat C; Toumi M; Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
[TBL] [Abstract][Full Text] [Related]
17. Overview of external reference pricing systems in Europe.
Rémuzat C; Urbinati D; Mzoughi O; El Hammi E; Belgaied W; Toumi M
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123181
[TBL] [Abstract][Full Text] [Related]
18. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
19. Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma.
Thielen FW; Heine RJSD; Berg SVD; Ham RMTT; Groot CAU
Cytotherapy; 2022 Dec; 24(12):1245-1258. PubMed ID: 36216697
[TBL] [Abstract][Full Text] [Related]
20. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
Iglesias-López C; Agustí A; Vallano A; Obach M
Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]